Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma

Leukemia volumeĀ 19,Ā pages 1497ā€“1499 (2005)Cite this article

TO THE EDITOR

In most patients with haematological malignancies treated with chemotherapy, growing resistance to cytostatics is observed. Multidrug resistance (MDR) is caused by enhanced cellular drug efflux following an increased activity of a membrane cell bound P-glycoprotein (Pgp), which is encoded by the mdr1 gene. Primary MDR in multiple myeloma (MM) is a rare, poorly understood phenomenon. A number of recent reports have shown that thalidomide (THAL) is an efficient drug in patients with refractory to chemotherapy MM.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Beck J, Handgretinger R, Dopfer R, Klingebiel T . Expression of mdr1, mrp, topoisomerase IIĪ±/Ī² and cyclin A in primary or relapsed states of acute lymphoblastic leukemias. Br J Haematol 1995; 89: 356ā€“363.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  2. Salmon SE, Dalton WS, Grojan TM . Multidrug resistant myeloma ā€“ laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991; 78: 44ā€“50.

    CASĀ  PubMedĀ  Google ScholarĀ 

  3. Weber D, Dimopoulos M, Sinicrope F, Alexanian R . VAD-cyclosporine for VAD-resistant myeloma. Leuk Lymphoma 1995; 19: 159ā€“163.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  4. Barlogie B, Velasquez WS, Alexanian R, Cabanillas F . Etoposide, dexamethasone, cytarabine and cisplatin in vincristine, doxorubicine and dexamethasone-refractory myeloma. J Clin Oncol 1989; 7: 1514ā€“1517.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  5. Singhal S, Metha J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565ā€“1571.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  6. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492ā€“494.

    ArticleĀ  CASĀ  PubMedĀ  Google ScholarĀ 

  7. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai Y-T et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943ā€“2950.

    CASĀ  PubMedĀ  Google ScholarĀ 

Download references

Acknowledgements

This work was supported by a grant from the State Committee for Scientific Research, No. KBN3PO5B05024.

Author information

Authors and Affiliations

  1. Department of Haematooncology and Bone Marrow Transplantation, Medical University of Lublin, Poland

    M Hus,Ā A DmoszyƱska,Ā I Hus,Ā D Jawniak,Ā M Adamczyk-CiochĀ &Ā N Grzasko

  2. Human Genetic Department, Medical University of Lublin, Poland

    J Kocki

Authors
  1. M Hus
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  2. A DmoszyƱska
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  3. J Kocki
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  4. I Hus
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  5. D Jawniak
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  6. M Adamczyk-Cioch
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

  7. N Grzasko
    View author publications

    You can also search for this author in PubMedĀ Google Scholar

Corresponding author

Correspondence to M Hus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hus, M., DmoszyƱska, A., Kocki, J. et al. Long-term thalidomide therapy resulted in lack of mdr1 gene expression in a patient with primary resistant multiple myeloma. Leukemia 19, 1497ā€“1499 (2005). https://doi.org/10.1038/sj.leu.2403811

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403811

Search

Advanced search

Quick links